EG BioMed

What EG BioMed does

EG BioMed Co., Ltd. (愛立基生醫) is a Taiwan-headquartered biomedical company founded in 2022 that develops and commercializes blood-based cancer detection tests based on cell-free DNA (cfDNA) methylation analysis. The company's core technology analyzes cancer-specific methylation patterns in circulating tumor DNA from an 8ml blood sample, producing results within 2-7 days without requiring fasting or time restrictions. The test portfolio, sold primarily under the OkaiDx brand in the US and EG-prefixed product names in Taiwan, includes pancreatic cancer detection (sensitivity >99%, specificity 93.3%, accuracy 94.2% on 100+ cases), breast cancer monitoring (95.7% sensitivity, 90.3% specificity, 95.4% accuracy on 500+ cases), colorectal cancer screening, a multi-cancer gastrointestinal panel (covering pancreatic, colorectal, and liver), and an EG-Aging Test for biological age assessment. Over 950 clinical samples have been analyzed cumulatively, with biomarker validation conducted in both Taiwanese and US populations, and proprietary biomarkers TMEM240 and ZNF781/ZFP30 identified via TCGA database analysis.

EG BioMed operates a hybrid go-to-market combining direct-to-consumer e-commerce (mdi.eg-bio.com, $289-299 per test inclusive of physician consultation), an EG Telehealth Platform jointly operated with YD Bio Limited covering 44 US states, Washington D.C., and Guam, in-clinic distribution through partners such as Myrostar Health in Bellevue, WA, clinical adoption at three Taipei Medical University-affiliated hospitals in Taiwan (TMUH, Wanfang, Shuang Ho), and exclusive technology licensing to YD Bio Limited for global commercialization of pancreatic cancer detection technology. The company holds CLIA and CAP-accredited laboratory operations in Bothell, Washington, and ISO 15189 and LDTs-certified operations in Taiwan, with active pursuit of FDA Breakthrough Devices Program designation. Patents have been granted across Taiwan, the EU (19 countries), China, Malaysia, the USA, Japan, Singapore, and Australia. EG BioMed has announced a planned 2026 merger with Nasdaq-listed YD Bio Limited (ticker: YDES), which would create an integrated data-driven oncology platform spanning early detection, real-world clinical data generation, and AI-enabled drug discovery.

Name

EG BioMed

Legal name

EG BioMed Co., Ltd.

Website

https://eg-bio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

EG BioMed is a Taiwan-founded biomedical company (2022) developing blood-based multi-cancer detection tests using cfDNA methylation technology, serving patients, hospitals, and consumers in Taiwan, the US, and Australia under the OkaiDx brand, with a planned 2026 merger into Nasdaq-listed YD Bio.

Ownership category

akta.pro rank

Product category

Liquid Biopsy Cancer Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Liquid biopsy diagnostics
• Cancer blood testing
• DNA methylation analysis
• Early cancer screening
• Laboratory developed tests

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Direct-to-Consumer Cancer Blood Test Sales (US): EG BioMed US Inc. sells OkaiDx cancer blood tests directly to consumers via its e-commerce platform (mdi.eg-bio.com). Tests are sold at $289-299 per test with physician consultation included. The company ships blood collection kits to customers' homes after physician approval.
2. Technology Licensing to YD Bio: EG BioMed has licensed its pancreatic cancer detection technology to YD Bio Limited for global commercialization. YD Bio is responsible for marketing, distribution, and通路 expansion in US markets, with EG BioMed receiving licensing royalties or revenue share.
3. CLIA/CAP-Certified Laboratory Services: The company's US laboratory (EG BioMed US Inc.) in Bothell, WA provides laboratory-developed tests (LDTs) for cancer detection. Services are offered as LDTs and are accredited under CLIA and CAP standards, serving healthcare providers and patients across the US.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

EG BioMed develops and commercializes blood-based cancer detection tests using proprietary cfDNA methylation analysis. The company operates the OkaiDx platform covering pancreatic, colorectal, breast, and gastrointestinal cancers, along with an aging assessment test, all requiring only 8ml of blood with results delivered within 2-7 days. The tests are conducted through its CLIA/CAP-certified laboratory in Bothell, Washington, and its ISO 15189-certified Taiwan laboratory.

Product overview

EG BioMed offers a unified multi-cancer liquid biopsy platform centered on DNA methylation blood testing technology. The OkaiDx™ product line provides four cancer-specific blood tests (pancreatic, colorectal, breast, and gastrointestinal cancer detection) using cfDNA methylation analysis, all performed in the company's CLIA/CAP-certified laboratory in Bothell, Washington. Supporting products include the EG-Aging Test for biological age assessment and the EG Telehealth Platform for decentralized clinical services. The portfolio operates as a platform-plus-modules architecture where the core OkaiDx brand underpins multiple cancer-type specific tests, with telehealth integration enabling nationwide service delivery.

Differentiator

Problem solved

Functional benefit

Brands

• OkaiDx: Blood-based cancer detection testing platform offered through EG BioMed US Inc. CLIA/CAP-certified laboratory, covering pancreatic, colorectal, breast, and gastrointestinal cancers
• EG-Pancreatic Blood Test-E1
• EG-Breast Blood Test-P1
• EG-Aging Test

Products and services

• OkaiDx Pancreatic Cancer Detection Blood Test A laboratory-developed test (LDT) for early detection of pancreatic cancer using DNA methylation analysis of 8ml blood sample. Demonstrated sensitivity >99%, specificity 93.3%, and accuracy 94.2% based on over 100 clinical cases. Targets high-risk groups including diabetic patients, those with family history of pancreatic cancer, and patients with chronic pancreatitis. Priced at $289 (promotional, regularly $500).
• OkaiDx Colorectal Cancer Detection Blood Test A blood-based colorectal cancer early screening test using cfDNA methylation technology, performed at the company's CLIA/CAP-certified laboratory in Washington State. Requires physician consultation and order review.
• OkaiDx Breast Cancer Monitoring Blood Test A non-invasive blood test for monitoring breast cancer recurrence or metastasis using cfDNA methylation technology, with 95.7% sensitivity, 90.3% specificity, and 95.4% accuracy based on over 500 clinical cases. Requires only 8ml of blood. ISO 15189 and LDTs certified. Priced at $289 (promotional, regularly $500).
• OkaiDx Gastrointestinal Cancer Detection Blood Test A comprehensive blood test for early health screening of three cancers (pancreatic, colorectal, and liver) using DNA methylation analysis. Detects early-stage gastrointestinal cancers with 93.8% success rate for pancreatic, 88.9% for colorectal, and 87.5% for liver cancers. Priced at $299 (promotional, regularly $600). Includes physician consultation.
• EG-Pancreatic Blood Test-E1 Non-invasive pancreatic cancer detection test using DNA methylation technology for the Taiwan market, requiring only 8ml of blood for early cancer risk assessment.

Quantifiable outcome

• Early-stage (Stage I/II) cancer detection rate of 93.8% for pancreatic, 88.9% for colorectal, 87.5% for liver cancer
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• YD Bio Limited (源點生物科技)coreStrategic or Co-development Partner · 31 March 2026EG BioMed and YD Bio jointly launched the EG Telehealth Platform covering 44 U.S. states, D.C., and Guam for cancer detection and decentralized clinical services. The companies have also entered into a non-binding MOU for a planned merger, anticipated to close in 2026 subject to regulatory approvals. The merger aims to create an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery.
• Taipei Medical University (TMU) and Affiliated Hospitals (TMUH, Wanfang, Shuang Ho)coreStrategic or Co-development PartnerEG BioMed's R&D is led by TMU Professor Ruo-Kai Lin (Chief Research Officer). The company's cancer detection platform has been approved for clinical adoption at three TMU-affiliated medical centers. Research collaboration spans breast cancer, colorectal cancer, and pancreatic cancer clinical studies since 2016-2018.
• YD Bio Limited — Technology LicensingcoreOEM/ Whitelabel/ Licensing PartnerEG BioMed has exclusively licensed its pancreatic cancer detection technology to YD Bio Limited for global commercialization. YD Bio is responsible for US market commercialization, marketing, and distribution. YD Bio listed on Nasdaq under ticker YDES in October 2025.
• Myrostar Health (Direct Primary Care)supportingChannel Partner/ Reseller/ DistributorMyrostar Health serves as a partner clinic in Bellevue, WA providing physician consultations and blood draw services for EG BioMed's cancer blood tests. The clinic evaluates whether patients qualify for the EG-Pancreatic Cancer Blood Test based on individual health needs. Tests are also available at Professional Medical Corporation and other designated clinics.
• EG BioMed AU Pty Ltd (Australia Subsidiary)supportingOthersAustralian subsidiary established in 2023 as part of EG BioMed's international market expansion strategy, extending the company's cancer detection services to the Australian market.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• GRAIL: GRAIL develops Galleri, a multi-cancer early-detection blood test using methylation-based cfDNA analysis. Direct competitor to EG BioMed's OkaiDx in the multi-cancer liquid biopsy screening market with similar biomarker approach but greater capital backing and commercial scale.
• Guardant Health: Guardant Health offers liquid biopsy tests including Guardant360 CDx for tumor profiling and Reveal for MRD/recurrence monitoring. Directly comparable to EG BioMed in cfDNA-based oncology diagnostics with established CLIA/CAP lab infrastructure and FDA-cleared products.
• Exact Sciences: Exact Sciences' Cologuard is a leading non-invasive colorectal cancer screening test, and the company has expanded into multi-cancer detection via the Thrive acquisition. Comparable to EG BioMed's colorectal blood test and broader cancer screening strategy through non-invasive blood-based diagnostics.
• Natera: Natera provides Signatera, a tumor-informed MRD/recurrence monitoring blood test, plus oncology and women's health cfDNA-based tests. Directly comparable to EG BioMed in liquid biopsy-based recurrence monitoring and treatment response assessment.

Emerging players

• Freenome: Freenome is developing a multiomics blood test for early cancer detection, with focus on colorectal cancer screening. Comparable in the multi-cancer early-detection space with a more multiomics-based approach versus EG BioMed's methylation-focused platform.
• Singlera Genomics: Singlera develops blood-based cancer screening tests including ColonES for early colorectal cancer detection. Comparable to EG BioMed as a methylation-based liquid biopsy company focused on single and multi-cancer early detection, with Asia-Pacific presence.
• Lucence Health: Lucence offers liquid biopsy tests for cancer detection and treatment selection with strong Asia-Pacific presence. Comparable to EG BioMed in cfDNA-based oncology diagnostics and US-Asia dual market positioning.
• Predicine: Predicine develops cfDNA and cfRNA-based liquid biopsy tests for cancer detection and monitoring with both US and China operations. Comparable to EG BioMed in methylation-based cfDNA liquid biopsy technology and cross-Pacific commercialization approach.

Regional players

• Burning Rock Biotech: China-based liquid biopsy company providing cfDNA-based cancer detection and therapy selection tests. Comparable in technology platform and Asian market presence, with stronger focus on therapy guidance and pharmaceutical services.
• MiRXES: Singapore-based liquid biopsy company developing multi-cancer early detection tests including GASTROClear, an Asia-focused gastric cancer screening test. Comparable to EG BioMed in Asia-region cfDNA-based cancer screening and direct-to-consumer testing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EG BioMed